Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012)

Boyd, Mark A and Dixit, Narendra M and Siangphoe, Umaporn and Buss, Neil E and Salgo, Miklos P and Lange, Joep MA and Phanuphak, Praphan and Cooper, David A and Perelson, Alan S and Ruxrungtham, Kiat (2006) Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). In: Journal of Infectious Diseases, 194 . pp. 1319-1322.

PDF Viral_Decay_Dynamics_in_HIV-Infected_Patients.pdf Restricted to Registered users only Download (264kB) | Request a copy

Abstract

The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean \pm SD elimination-rate constant for overall decay ( 0.142 \pm 0.040 per day and 0.128 \pm 0.033 per day in the 2- and 3-target arms, respectively; P>.1) or for modeled first-phase decay rate ( -0.62 \pm 0.34 per day and -0.51 \pm 0.16 per day; P >.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.

Item Type:	Journal Article
Publication:	Journal of Infectious Diseases
Publisher:	University of Chicago Press
Additional Information:	Copyright of this article belongs to University of Chicago Press.
Department/Centre:	Division of Mechanical Sciences > Chemical Engineering
Date Deposited:	29 May 2008
Last Modified:	19 Sep 2010 04:45
URI:	http://eprints.iisc.ac.in/id/eprint/14079

Actions (login required)

View Item